AP-1 as a Regulator of MMP-13 in the Stromal Cell of Giant Cell Tumor of Bone
Author(s) -
Isabella W.Y. Mak,
Robert Turcotte,
Snežana Popović,
Gurmit Singh,
Michelle Ghert
Publication year - 2011
Publication title -
biochemistry research international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.631
H-Index - 36
eISSN - 2090-2255
pISSN - 2090-2247
DOI - 10.1155/2011/164197
Subject(s) - stromal cell , runx2 , transcription factor , gene knockdown , matrix metalloproteinase , cancer research , stromal cell derived factor 1 , cell , giant cell tumor of bone , microbiology and biotechnology , regulator , biology , cell culture , medicine , pathology , immunology , gene , chemokine , cxcr4 , inflammation , giant cell , genetics
Matrix-metalloproteinase-13 (MMP-13) has been shown to be an important protease in inflammatory and neoplastic conditions of the skeletal system. In particular, the stromal cells of giant cell tumor of bone (GCT) express very high levels of MMP-13 in response to the cytokine-rich environment of the tumor. We have previously shown that MMP-13 expression in these cells is regulated, at least in part, by the RUNX2 transcription factor. In the current study, we identify the expression of the c-Fos and c-Jun elements of the AP-1 transcription factor in these cells by protein screening assays and real-time PCR. We then used siRNA gene knockdown to determine that these elements, in particular c-Jun, are upstream regulators of MMP-13 expression and activity in GCT stromal cells. We conclude that there was no synergy found between RUNX2 and AP-1 in the regulation of the MMP13 expression and that these transcription factors may be independently regulated in these cells.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom